studies

la/mBC - HR-positive - 1st line (L1), capivasertib plus paclitaxel vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias progression or deaths (PFS)detailed resultsBEECH, 2019 0.80 [0.60; 1.06] 0.80[0.60; 1.06]BEECH, 201910%110NAnot evaluable objective responses (ORR)detailed resultsBEECH, 2019 1.09 [0.51; 2.33] 1.09[0.51; 2.33]BEECH, 201910%110NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-05-10 00:42 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 352,354 - treatments: 1278